Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | GAK | O14976 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.42 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915158 | 1.00 | DYRK1B (0.47) | DYRK1BPARP1CCNCCDK8NR4A2 | |
| SCHEMBL1618081 | 0.84 | NR4A2 (0.43) | DYRK1BNR4A2GAKAXLPRKCI | |
| SCHEMBL17059461 | 0.79 | PARP1 (0.47) | PARP1CCNCCDK8NR4A2GAK | |
| SCHEMBL1888577 | 0.79 | NR4A2 (0.66) | DYRK1BPARP1CCNCCDK8NR4A2 | |
| SCHEMBL30051309 | 0.79 | NR4A2 (0.66) | DYRK1BPARP1CCNCCDK8NR4A2 | |
| SCHEMBL20733040 | 0.76 | PARP1 (0.44) | DYRK1BPARP1CCNCCDK8NR4A2 | |
| SCHEMBL599975 | 0.76 | PARP1 (0.44) | PARP1CCNCCDK8NR4A2GAK | |
| SCHEMBL18970831 | 0.76 | PARP1 (0.44) | PARP1CCNCCDK8NR4A2GAK | |
| SCHEMBL31355748 | 0.76 | SMN1; SMN2 (0.51) | PARP1CCNCCDK8NR4A2GAK | |
| SCHEMBL14075851 | 0.76 | SMN1; SMN2 (0.51) | PARP1CCNCCDK8NR4A2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240190904-A1 | Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024078513-A1 | CONDENSED AZINES FOR TREATING CANCER | CHENGDU ANTICANCER BIOSCIENCE , LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-4330233-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4322947-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF RIP2 KINASE, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2024-02-21 | — | — | EP | disclosed |
| EP-3615538-B1 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-101023080-A | Thiazolinone 4-monosubstituted quinolines | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137395-A1 | Novel quinoline derivatives | AGOURON PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | DYRK1B 4403/4885PARP1 3679/4885CCNC 2945/4885 |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | DYRK1B 674/4885PARP1 202/4885CCNC 51/4885 |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | DYRK1B 1225/4885PARP1 566/4885CCNC 35/4885 |
| US-20240190904-A1 | Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof | RIPK2, RIPK1, RIPK3 | DYRK1B 2336/4885PARP1 397/4885CCNC 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.